Evolution of clinical guidelines for antimicrobial management of <i>Clostridioides difficile</i> infection.

Ther Adv Gastroenterol · 2021 · PMC8111514 · PMID 33995583

Europe PMC DOI

hedged sentence

0.1100

closest p · 2.2× alpha

0.1100

boldest claim

The sentences

showed a trendp = 0.11not close (p > 0.1)

Those who received the rifaximin showed a trend for decreased rates of recurrence of CDI (31% versus 15%, p = 0.11). 29 Adding the option of a rifaximin chaser provided the practicing clinician with another choice for those with multiply recurrent CDI.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.